详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

TGF-β in renal fibrosis: triumphs and challenges

18| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Nephrology & Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China [2]Department of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China [3]Guangdong-Hong Kong Joint Laboratory for Immunity & Genetics of Chronic Kidney Disease, Guangdong Academy of Medical Sciences, Guangdong Provincial People’s Hospital, Guangzhou, China [4]Guangdong-Hong Kong Joint Laboratory for Immunity & Genetics of Chronic Kidney Disease, Chinese University of Hong Kong, Hong Kong, China

出处：

DOI：

ISSN：

关键词： immune cells inflammation renal fibrosis TGF-beta therapy

摘要：

Renal fibrosis is a hallmark of chronic kidney disease. Although considerable achievements in the pathogenesis of renal fibrosis have been made, the underlying mechanisms of renal fibrosis remain largely to be explored. Now we have reached the consensus that TGF-beta is a master regulator of renal fibrosis. Indeed, TGF-beta regulates renal fibrosis via both canonical and noncanonical TGF-beta signaling. Moreover, ongoing renal inflammation promotes fibrosis as inflammatory cells such as macrophages, conventional T cells and mucosal-associated invariant T cells may directly or indirectly contribute to renal fibrosis, which is also tightly regulated by TGF-beta. However, anti-TGF-beta treatment for renal fibrosis remains ineffective and nonspecific. Thus, research into mechanisms and treatment of renal fibrosis remains highly challenging.

基金：

基金编号： GRF 14121816 14163317 14117418 14104019 R4012-18F C7018-16G HMRF 0314048 05161326 06173986 14152321 2017B030314166 81873261 81903956 20201133 2019B121205005

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 2 区医学

小类 | 2 区药物化学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区药物化学

JCR分区：

出版当年[2018]版：

Q2 CHEMISTRY, MEDICINAL

最新[2023]版：

Q3 CHEMISTRY, MEDICINAL

影响因子： 3.2 最新[2023版] 3.7 最新五年平均 3.617 出版当年[2018版] 3.884 出版当年五年平均 3.969 出版前一年[2017版] 3.607 出版后一年[2019版]

第一作者：

第一作者机构： [1]Department of Nephrology & Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China [2]Department of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China

通讯作者：

通讯机构： [2]Department of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China [3]Guangdong-Hong Kong Joint Laboratory for Immunity & Genetics of Chronic Kidney Disease, Guangdong Academy of Medical Sciences, Guangdong Provincial People’s Hospital, Guangzhou, China [4]Guangdong-Hong Kong Joint Laboratory for Immunity & Genetics of Chronic Kidney Disease, Chinese University of Hong Kong, Hong Kong, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Smad3 Signatures in Renal Inflammation and Fibrosis [2]Diverse Role of TGF-β in Kidney Disease [3]Transforming Growth Factor-β and Long Non-coding RNA in Renal Inflammation and Fibrosis [4]Endophilin A2 protects against renal fibrosis by targeting TGF-β/Smad signaling [5]Role of TGF-Beta Signaling in Beta Cell Proliferation and Function in Diabetes. [6]Deletion of Smad3 protects against C-reactive protein-induced renal fibrosis and inflammation in obstructive nephropathy. [7]Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-β/Smad and NF-κB signaling pathway in 5/6 nephrectomized rats. [8]Therapeutic Potential for Renal Fibrosis by targeting Smad3-dependent Non-coding RNAs [9]Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy. [10]Effects of andrographolide on renal tubulointersticial injury and fibrosis. Evidence of its mechanism of action.